Several studies have suggested that LRP1B mutation was correlated with high TMB and improved outcomes with ICIs monotherapy in melanoma, NSCLC, and other solid tumors, which are consistent with our results in ICIs plus chemotherapy [36–40]. Here, LRP1B is linked to melanoma.